Candel Therapeutics Inc Stock

$5.13

4.29% yesterday

Nasdaq, Jun 13, 10:00 pm CET

ISIN

US1374041093

Symbol

CADL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Overview Dividends Analysts Charts News Strategies

Candel Therapeutics Inc Stock price

$5.13

-1.87 26.71% 5Y

Nasdaq, Closing price Fri, Jun 13 2025

-0.23 4.29%

ISIN

US1374041093

Symbol

CADL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Services

Industry

Various services

Key metrics

Market capitalization	$257.03m
Enterprise Value	$174.94m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	3.38
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-33.60m
Free Cash Flow (TTM) Free Cash Flow	$-27.21m
Cash position	$92.17m
EPS (TTM) EPS	$-0.72
P/E forward	negative
Short interest	15.22%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Candel Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Candel Therapeutics Inc forecast:

4x Buy

100%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Candel Therapeutics Inc forecast:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Candel Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	14 14	6% 6% -
- Research and Development Expense	18 18	16% 16% -
EBITDA	-33 -33	9% 9% -
- Depreciation and Amortization	1.01 1.01	4% 4% -
EBIT (Operating Income) EBIT	-34 -34	8% 8% -
Net Profit	-40 -40	6% 6% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Candel Therapeutics Inc Stock News

Positive

Proactive Investors

●

8 days ago

Candel Therapeutics adds biotech veteran Maha Radhakrishnan to Board

Candel Therapeutics Inc (NASDAQ:CADL) has appointed biotechnology industry veteran Maha Radhakrishnan, M.D., to its board of directors.

Neutral

GlobeNewsWire

●

8 days ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development Appointment of seasoned strategic industry executive strengthens the Board of Directors as Candel advances toward Biologics License Application submission and commercial development

Positive

Proactive Investors

●

17 days ago

Candel Therapeutics get FDA's RMAT designation for prostate cancer therapy

Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead immunotherapy candidate, CAN-2409, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease. The RMAT designation is intended to expedite the development and review ...

More Candel Therapeutics Inc News

Company Profile

Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Head office	United States
CEO	Paul-Peter Tak
Employees	42
Founded	2002
Website	www.candeltx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now